TriangleMezigdomide (NCT06627751)
Mezigdomide trial for Extramedullary Disease in Multiple Myeloma (NCT06627751). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with relapsed or refractory multiple myeloma after at least one treatment line, with a biopsy-accessible extramedullary or paraskeletal lesion.
The idea: mezigdomide promotes breakdown of selected proteins; carfilzomib blocks protein disposal, and dexamethasone targets myeloma cells. Treatment combines oral mezigdomide on days 1–21, carfilzomib infusions on days 1, 8, and 15, and weekly oral dexamethasone. Six 28-day cycles assess responses. Tumor and marrow biopsies are part of the study.
This phase 2 study plans 28 patients. Jens Hillengass leads at Roswell Park in Buffalo, one recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.